Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer

- Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry -

Brent Pfeiffenberger, Pharm.D., MBA

PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board, effective December 4, 2023. A proven leader with over 20 years of global experience across the healthcare industry, Dr. Pfeiffenberger most recently served as Chief Operating Officer at Neogene Therapeutics, a wholly owned subsidiary of AstraZeneca focused on developing cell therapies for the treatment of cancer. In connection with the appointment, Greg Russotti, Ph.D., who has served as Century’s Interim Chief Executive Officer since April 2023, will assume the role of Chief Technology and Manufacturing Officer, an expanded role from his previous position as Chief Technology Officer.

“Brent is a strong leader with extensive experience across the research, development, and commercialization of lifesaving drugs. His unique strategic leadership and operational acumen will serve Century well, and we are thrilled to have him join as Chief Executive Officer,” said Joe Jimenez, Chairman of the Board. “On behalf of the entire Board, I would like to thank Greg Russotti for his exceptional leadership and unwavering dedication during the interim period. We look forward to his continued contributions in the newly created role of Chief Technology and Manufacturing Officer, as Century looks to leverage its manufacturing expertise and state-of-the-art GMP manufacturing facility to generate additional value.”

“Century is a pioneer on the cutting-edge of the allogeneic cell therapy space, and with its first clinical data readout expected by year-end, it is an honor to join as Chief Executive Officer at this exciting time,” said Dr. Pfeiffenberger. “Leveraging the proprietary Allo-Evasion platform, the Company is uniquely positioned to develop differentiated allogeneic cell therapies and expand patient access to life-saving medicines. I look forward to working alongside Greg and the talented Century team to continue to advance the Company’s innovative pipeline and serve patients in need.”